Thr74

Site Information
RGLKGPGtPAFPHyL SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 455780

In vivo Characterization
Methods used to characterize site in vivo:	[32P] bio-synthetic labeling ( 8 ) , immunoprecipitation ( 7 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 ) , mutation of modification site ( 7 ) , phosphoamino acid analysis ( 8 ) , western blotting ( 7 )
Relevant cell line - cell type - tissue:	32Dcl3 (myeloid) ( 7 ) , COS (fibroblast) ( 7 ) , Jurkat (T lymphocyte) ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 )

Downstream Regulation
Effects of modification on C/EBP-epsilon:	molecular association, regulation ( 7 )
Effects of modification on biological processes:	cell differentiation, altered ( 7 ) , transcription, induced ( 7 , 8 )
Induce interaction with:	DNA ( 7 ) , NFkB-p65 (human) ( 7 )

References
1	Mulhern D (2012) CST Curation Set: 13339; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
2	Mulhern D (2012) CST Curation Set: 13340; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
3	Mulhern D (2011) CST Curation Set: 12551; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
4	Guo A (2011) CST Curation Set: 12018; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
5	Guo A (2011) CST Curation Set: 12020; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
6	Guo A (2011) CST Curation Set: 12022; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
7	Chumakov AM, Silla A, Williamson EA, Koeffler HP (2007) Modulation of DNA binding properties of CCAAT/enhancer binding protein epsilon by heterodimer formation and interactions with NFkappaB pathway. Blood 109, 4209-19 17255362 Curated Info
8	Williamson EA, et al. (2005) CCAAT/enhancer binding protein epsilon: changes in function upon phosphorylation by p38 MAP kinase. Blood 105, 3841-7 15677566 Curated Info